JP2018509907A5 - - Google Patents

Info

Publication number

JP2018509907A5

JP2018509907A5 JP2017548919A JP2017548919A JP2018509907A5 JP 2018509907 A5 JP2018509907 A5 JP 2018509907A5 JP 2017548919 A JP2017548919 A JP 2017548919A JP 2017548919 A JP2017548919 A JP 2017548919A JP 2018509907 A5 JP2018509907 A5 JP 2018509907A5

Authority

JP

Japan

Prior art keywords

amino acid

acid sequence

seq

cdr2

cdr3

Prior art date

2016-03-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 982
• 230000027455 binding Effects 0.000 claims description 377
• 239000000427 antigen Substances 0.000 claims description 321
• 102000036639 antigens Human genes 0.000 claims description 321
• 108091007433 antigens Proteins 0.000 claims description 321
• 239000012634 fragment Substances 0.000 claims description 246
• 210000004027 cell Anatomy 0.000 claims description 197
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 83
• 102100023123 Mucin-16 Human genes 0.000 claims description 83
• 238000000338 in vitro Methods 0.000 claims description 52
• 108010082117 matrigel Proteins 0.000 claims description 52
• 230000009545 invasion Effects 0.000 claims description 51
• 238000000034 method Methods 0.000 claims description 49
• 229910052757 nitrogen Inorganic materials 0.000 claims description 32
• 230000013595 glycosylation Effects 0.000 claims description 31
• 238000006206 glycosylation reaction Methods 0.000 claims description 31
• 108091033319 polynucleotide Proteins 0.000 claims description 24
• 102000040430 polynucleotide Human genes 0.000 claims description 24
• 239000002157 polynucleotide Substances 0.000 claims description 24
• 125000000539 amino acid group Chemical group 0.000 claims description 22
• QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 claims description 19
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 11
• 239000003814 drug Substances 0.000 claims description 11
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
• 150000007523 nucleic acids Chemical group 0.000 claims description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• 229910052698 phosphorus Inorganic materials 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 7
• 229940127089 cytotoxic agent Drugs 0.000 claims description 7
• 239000002254 cytotoxic agent Substances 0.000 claims description 7
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
• 229940079593 drug Drugs 0.000 claims description 7
• 239000012216 imaging agent Substances 0.000 claims description 7
• 108060003951 Immunoglobulin Proteins 0.000 claims description 6
• 102000018358 immunoglobulin Human genes 0.000 claims description 6
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
• 150000001413 amino acids Chemical class 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 210000000481 breast Anatomy 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 210000003101 oviduct Anatomy 0.000 claims description 2
• 210000000496 pancreas Anatomy 0.000 claims description 2
• 210000004291 uterus Anatomy 0.000 claims description 2
• 201000005296 lung carcinoma Diseases 0.000 claims 1
• 210000001672 ovary Anatomy 0.000 claims 1
• 210000004303 peritoneum Anatomy 0.000 claims 1
• 230000002163 immunogen Effects 0.000 description 54
• DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 53
• 108010015899 Glycopeptides Proteins 0.000 description 53
• 102000002068 Glycopeptides Human genes 0.000 description 53
• 150000001720 carbohydrates Chemical class 0.000 description 14
• 108020001507 fusion proteins Proteins 0.000 description 7
• 102000037865 fusion proteins Human genes 0.000 description 7
• 150000002016 disaccharides Chemical class 0.000 description 6
• 229940127121 immunoconjugate Drugs 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 5
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 108010078791 Carrier Proteins Proteins 0.000 description 4
• 108090000288 Glycoproteins Proteins 0.000 description 4
• 102000003886 Glycoproteins Human genes 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
• ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical class CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 150000002772 monosaccharides Chemical class 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 150000004044 tetrasaccharides Chemical class 0.000 description 2
• 150000004043 trisaccharides Chemical class 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 201000001342 Fallopian tube cancer Diseases 0.000 description 1
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 150000001508 asparagines Chemical class 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1